Skip to main content
Clinical Trials/NCT05463887
NCT05463887
Active, not recruiting
Not Applicable

Personalized Disease Prevention (PDP): A Randomized Clinical Trial

Glen Taksler1 site in 1 country660 target enrollmentAugust 5, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Primary Prevention
Sponsor
Glen Taksler
Enrollment
660
Locations
1
Primary Endpoint
Change in quality-adjusted life expectancy
Status
Active, not recruiting
Last Updated
4 months ago

Overview

Brief Summary

This study will evaluate whether patients and their providers benefit from an evidence-based decision tool to help prioritize preventive (and select chronic disease management) services based on their potential to improve quality-adjusted life expectancy, individualized for patient risk factors. The study seeks to enroll 600 patients and 60 primary care providers. Half of providers will be assigned to an intervention to utilize the decision tool with approximately 10 high-priority patients each (patients of particular interest to the research study, on whom follow-up outcomes will be collected), and half will be assigned to usual care.

Surveys will be administered at baseline and approximately 6 months later; electronic health records data on preventive service utilization will be collected; and optional qualitative interviews may be conducted.

Detailed Description

The study will evaluate whether patients and their providers benefit from an evidence-based decision tool to help prioritize preventive services based on their potential to improve quality-adjusted life expectancy, individualized for patient risk factors. This partially-blinded study seeks to enroll 600 patients and 60 primary care providers. Half of providers will be assigned to an intervention to utilize the decision tool with approximately 10 high-priority patients each (patients of particular interest to the research study, on whom follow-up outcomes will be collected) and half will be assigned to usual care. It is hypothesized that quality-adjusted life expectancy will increase by more in high-priority patients who receive the intervention, as compared with a control group. Objectives: Primary objective: To measure whether use of individualized preventive care recommendations is likely to help patients live a longer, healthier life. Secondary objectives: 1. To measure whether use of individualized preventive care recommendations is likely to help patients live a longer life 2. To assess comprehension of the decision tool 3. To assess readiness to change 4. To assess use of shared decision-making 5. To measure outcomes for specific preventive services

Registry
clinicaltrials.gov
Start Date
August 5, 2022
End Date
January 31, 2026
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Glen Taksler
Responsible Party
Sponsor Investigator
Principal Investigator

Glen Taksler

Staff, Cleveland Clinic and Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine

The Cleveland Clinic

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in quality-adjusted life expectancy

Time Frame: 6 months

Change in quality-adjusted life expectancy for high-priority patients in the intervention arm, as compared with the control arm.

Secondary Outcomes

  • Change in life expectancy(Through study completion, approximately 2 to 3 years on average)
  • Service least likely to improve quality-adjusted life expectancy(Within 3 business days of baseline encounter)
  • Weight loss(6 months (12 months and all follow-up time points may be assessed))
  • Systolic blood pressure(6 months (12 months and all follow-up time points may be assessed))
  • Shared decision-making(Within 3 business days of baseline encounter)
  • Service most likely to improve quality-adjusted life expectancy(Within 3 business days of baseline encounter)
  • True age(Within 3 business days of baseline encounter)
  • Readiness to change (bottom-ranked)(Within 3 business days of baseline encounter)
  • Change in quality-adjusted life expectancy(Through study completion, approximately 2 to 3 years on average)
  • Readiness to change (top-ranked)(Within 3 business days of baseline encounter)
  • HbA1c(6 months (12 months and all follow-up time points may be assessed))
  • Cardiovascular disease risk(6 months (12 months and all follow-up time points may be assessed))
  • Healthy diet(6 months (12 months and all follow-up time points may be assessed))
  • Breast cancer screening(6 months (12 months and all follow-up time points may be assessed))
  • LDL cholesterol(6 months (12 months and all follow-up time points may be assessed))
  • Physical activity(6 months (12 months and all follow-up time points may be assessed))
  • Alcohol misuse(6 months (12 months and all follow-up time points may be assessed))
  • Tobacco cessation(6 months (12 months and all follow-up time points may be assessed))
  • Cervical cancer screening(6 months (12 months and all follow-up time points may be assessed))
  • Colorectal cancer screening(6 months (12 months and all follow-up time points may be assessed))
  • Lung cancer screening(6 months (12 months and all follow-up time points may be assessed))
  • Total cholesterol(6 months (12 months and all follow-up time points may be assessed))

Study Sites (1)

Loading locations...

Similar Trials